Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Rejection Clear all
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting No phase listed Observational

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

NCT07516379
View directory record Official record
Conditions
Lung Transplant, End Stage Lung Disease, Rejection
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 4 Interventional

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Phase 2 Interventional Results available

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

NCT03473340
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions
Pirfenidone Capsule, Placebo Capsule
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

NCT04057742
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jul 22, 2026, 12:34 PM EDT
Active, not recruiting No phase listed Observational

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

NCT03859388
View directory record Official record
Conditions
Rejection Chronic Renal, Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

NCT03317925
View directory record Official record
Conditions
Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions
Renal Transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Year to 20 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?

NCT00340951
View directory record Official record
Conditions
Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo

NCT01033201
View directory record Official record
Conditions
Lung Transplant
Interventions
Confocal imaging
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Jul 22, 2026, 12:34 PM EDT
Completed No phase listed Observational

Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)

NCT00611702
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney biopsy
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Jul 22, 2026, 12:34 PM EDT
Active, not recruiting Phase 2 Interventional

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

NCT03697395
View directory record Official record
Conditions
Chronic Rejection of Lung Transplant
Interventions
Lung transplant recipient without MRI imaging, Lung transplant recipient with MRI imaging
Diagnostic Test · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 22, 2026, 12:34 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow up of the LTOG Cohort

NCT04787822
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Enrolling by invitation No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

NCT04941573
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

NCT03321656
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Envarsus XR
Drug
Lead sponsor
Roberto Gedaly
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jul 22, 2026, 12:34 PM EDT